RAFAEL HOLDINGS INC. CLASS B COMMON STOCK

Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022

27 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

16 Jun 2022 13:14:18 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

16 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

14 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

24 May 2022 10:04:10 By Nasdaq GlobeNewswire

Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.

19 May 2022 08:00:02 By Nasdaq GlobeNewswire

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

17 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

21 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

18 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

06 Jan 2022 07:30:01 By Nasdaq GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results

15 Dec 2021 15:30:00 By Nasdaq GlobeNewswire

Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus

22 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

11 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma

03 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

28 Oct 2021 07:00:02 By Nasdaq GlobeNewswire

Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

28 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

18 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update

18 Oct 2021 15:30:00 By Nasdaq GlobeNewswire